Results to be presented during the tumor biology session at the ASCO
2018 Annual Meeting
Company Website:
http://www.nanthealth.com
CHICAGO -- (Business Wire)
NantWorks,
LLC today announced that its affiliate companies, NantHealth,
Inc., (NASDAQ: NH), a leading next-generation, evidence-based,
personalized healthcare company and NantOmics,
LLC, the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, will present data on next-generation sequencing
of paired DNA and RNA analysis in patients with rare and ultra-rare
cancers during the tumor biology sessionat the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event
bringing together 30,000 oncology professionals from June 1-5, 2018 at
McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at
booth #7147 during the event.
“New data shows that matched targeted therapy may result in responses
for patients with rare and ultra-rare tumors,” said Patrick Soon-Shiong,
MD, founder of NantWorks. “We look forward to sharing these results as
we continue on our path to building a future of personalized and
improved care.”
Presentation Details
Genomic
Landscape of Diverse Rare Tumors: Next-Generation Sequencing of Paired
DNA and RNA analysis, Abstract #12114
WHO:
NantHealth, LLC and NantOmics, LLC
WHAT: Tumor Biology
Session
WHEN: June 4, 1:15-4:45 PM CST
WHERE:
Hall A, McCormick Place
Presentation Summary
The 286 patients involved in this study had been diagnosed with rare
tumor diagnoses. Somatic-specific variants were identified using paired
tumor/normal comprehensive NGS. Analysis was focused on the 200 most
frequently mutated genes in this cohort, and deep whole transcriptomic
sequencing was used to determine expression of observed somatic
variants. The results found that most patients with rare and ultra-rare
cancers had theoretically tractable alteration, yet not all the DNA
alterations were seen in RNA level, indicating potential silencing at
the RNA level.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissue and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system that integrates our unique
molecular profiling solution, software and hardware. Our system
infrastructure collects, indexes, analyzes and interprets billions of
molecular, clinical, operational and financial data points derived from
novel and traditional sources to continuously improve decision-making
and optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular diagnostic capabilities with the intent of providing
actionable intelligence and molecularly driven decision support for
cancer patients and their providers at the point of care. NantOmics is
the first molecular diagnostics company to pioneer an integrated
approach to unearthing the genomic and proteomic variances that initiate
and drive cancer, by analyzing both normal and tumor cells from the same
patient and following identified variances through from DNA to RNA to
protein to drug. NantOmics has a highly scalable cloud-based
infrastructure capable of storing and processing thousands of genomes a
day, computing genomic variances in near real-time, and correlating
proteomic pathway analysis with quantitative multi-plexed protein
expression analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180602005093/en/
Contacts:
NANT
Jen Hodson
jhodson@nantworks.com
or
NANT
Henry
C. Jackson
cj@nantworks.com
Source: NantHealth, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.